Salvage TACE for unresectable HCC: switching the chemotherapeutic agents.

Salvage TACE for unresectable HCC: switching the chemotherapeutic agents. - Switching chemotherapeutic agents in TACE

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015887

Enrollment

200

Registered

2014-12-09

Start date

2013-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable hepatocellular carcinoma

Interventions

treatment regimens

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) HCC is diagnosed on the basis of positive results in pathology and/or radiologic imagings 2) Patients are not eligible for surgical resection or percutaneous ablation 3) Efficacy after the first-line TACE using epirubicin-lipiodol is progressive disease.

Exclusion criteria

Exclusion criteria: 1)HCC with macrovascular invasion and/or extrahepatic metastasis 2)Child-Pugh score =/> 10 3)Patients who cannot be performed TACE technically 4)Patients received previous cisplatin-based chemotherapy 5)Patients received previous systemic chemotherapy

Design outcomes

Primary

Measure	Time frame
Efficacy and safety of second-line TACE	—

Countries

Japan

Contacts

Public ContactYoshihiro Goda

Kanagawa Cancer Center Hepatobiliary and Pancreatic Oncology

y-gouda@kcch.jp+81-45-520-2222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026